Monday, December 3, 2018
Casi Pharmaceuticals announces China market approval for EVOMELA
CASI Pharmaceuticals announces that it has received National Medical Products Administration approval of Melphalan Hydrochloride For Injection for: use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma, and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
https://thefly.com/landingPageNews.php?id=2831103
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.